Ginkgo Bioworks Holdings (DNA) revenue breakdown
By segment, Cell Engineering is the largest at 57% of fiscal 2023 revenue, growing 13% a year over 2 years.
By product, Cell Engineering is the largest at 78% of fiscal 2025 revenue, growing 4% a year over 4 years.
Revenue by segment
Fiscal years, as Ginkgo Bioworks Holdings reports them in its 10-K filings; fiscal 2023 total $251M.
| Segments | 2021 | 2022 | 2023 | Share |
|---|---|---|---|---|
| Cell Engineering | $113M | $144M | $144M | 57% |
| Biosecurity | $201M | $334M | $108M | 43% |
Revenue by product
Fiscal years, as Ginkgo Bioworks Holdings reports them in its 10-K filings; fiscal 2025 total $170M.
| Products | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|
| Cell Engineering | $113M | $144M | $144M | $174M | $133M | 78% |
| Service | $178M | $299M | $79M | $53M | $37M | 22% |
| Product | — | — | $29M | — | — | — |
| Product | $23M | $35M | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DNA.
Open DNA in InvestinglyQuestions
Where does Ginkgo Bioworks Holdings make its money?
In fiscal 2023, by segment: Cell Engineering $144M, Biosecurity $108M.
From Ginkgo Bioworks Holdings's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.